Smith & Nephew cuts profit forecast, faces growth challenges despite some revenue gains

Smith & Nephew has lowered its full-year revenue growth forecast to 3% and halved its expected trading profit growth to around 4%, citing weakness in its US Orthopaedics division. While all three business divisions showed revenue growth year-to-date, including strong double-digit gains in Sports Medicine & ENT, the US Hips and Knees segment remains weak. The company's shares appear fully valued at current earnings multiples, leading to a downgrade to 'hold' due to limited near-term growth catalysts. This signals challenges ahead for Smith & Nephew's profitability and growth outlook despite some positive revenue trends.

As of Nov 07, 2026 01:01 WIB, Smith & Nephew (SNN) shares are trading at USD 31.11 on Pluang, down 2.83% for the day. The stock's market capitalization stands at $13.34 billion, with a dividend yield of 2.48%. Despite the recent downgrade to 'hold' due to sluggish growth and a cautious outlook, the stock remains actively traded with a volume of 2,818,360 shares.